2023
Overall survival in low-comorbidity patients with stage I non–small cell lung cancer who chose stereotactic body radiotherapy compared to surgery
Udelsman B, Canavan M, Zhan P, Ely S, Park H, Boffa D, Mase V. Overall survival in low-comorbidity patients with stage I non–small cell lung cancer who chose stereotactic body radiotherapy compared to surgery. Journal Of Thoracic And Cardiovascular Surgery 2023, 167: 822-833.e7. PMID: 37500052, DOI: 10.1016/j.jtcvs.2023.07.021.Peer-Reviewed Original ResearchNon-small cell lung cancerStereotactic body radiotherapyStage I non-small cell lung cancerLow-comorbidity patientsCell lung cancerOverall survivalSurgical managementLung cancerSurgical resectionBody radiotherapyClinical stage I non-small cell lung cancerEarly-stage non-small cell lung cancerPropensity score-matched cohortPropensity score-matched patientsPropensity score-matched analysisEarly-stage lung cancerLong-term OSNational Cancer DatabaseProportion of patientsCancer DatabasePatientsSBRT patientsSurgeryCancerMortality
2022
Utilization and Survival Impact of Hypofractionated Radiotherapy in Stage I Non-small Cell Lung Cancer
Saeed N, Jin L, Amini A, Verma V, Lester-Coll N, Chen P, Decker R, Park H. Utilization and Survival Impact of Hypofractionated Radiotherapy in Stage I Non-small Cell Lung Cancer. American Journal Of Clinical Oncology 2022, 46: 66-72. PMID: 36662872, DOI: 10.1097/coc.0000000000000974.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStage I non-small cell lung cancerOverall survivalCell lung cancerLung cancerStereotactic body radiation therapyNational Cancer DatabaseLog-rank testBody radiation therapyOptimal fractionation scheduleMultivariable modeling techniquesOS benefitHypofractionated radiotherapySurvival impactMultivariable analysisCox regressionCancer DatabaseRetrospective analysisFractionation schedulesRadiation therapyHFRTPatientsCFRTRadiotherapyKaplan-Meier estimatorImmunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Park HS, Goldberg SB, Boffa DJ. Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer. JAMA Network Open 2022, 5: e2224478. PMID: 35925606, PMCID: PMC9353596, DOI: 10.1001/jamanetworkopen.2022.24478.Peer-Reviewed Original ResearchConceptsStage III non-small cell lung cancerNon-small cell lung cancerClinical stage III non-small cell lung cancerUnresectable stage III non-small cell lung cancerPropensity-matched sampleGeneral US populationSurvival advantageCohort studyLung cancerMultivariable Cox proportional hazards modelsUS populationStage III lung cancerMedian age 66 yearsCox proportional hazards modelNational Cancer DatabaseEfficacy of immunotherapyAge 66 yearsProtocol rangesCell lung cancerClinical trial populationsProportional hazards modelTerms of ageImmunotherapy initiationImmunotherapy recipientsImmunotherapy useNonadherence to Multimodality Cancer Treatment Guidelines in the United States
Tchelebi LT, Shen B, Wang M, Potters L, Herman J, Boffa D, Segel JE, Park HS, Zaorsky NG. Nonadherence to Multimodality Cancer Treatment Guidelines in the United States. Advances In Radiation Oncology 2022, 7: 100938. PMID: 35469182, PMCID: PMC9034283, DOI: 10.1016/j.adro.2022.100938.Peer-Reviewed Original ResearchGuideline-concordant treatmentAnal cancerMultimodality treatmentRectal cancerCervical cancerLung cancerAdvanced non-small cell lung cancerNasopharynx cancerNon-small cell lung cancerNonmetastatic anal cancerNational Cancer DatabasePercent of patientsAdvanced cervical cancerCancer treatment guidelinesCell lung cancerMultivariable logistic regressionPrimary tumor siteLow-volume facilitiesTreatment guidelinesComorbid conditionsCancer DatabaseOdds ratioNational guidelinesPatientsConfounding variables
2021
Post-operative radiation therapy for non-small cell lung cancer: A comparison of radiation therapy techniques
Jairam V, Pasha S, Soulos PR, Gross CP, Yu JB, Park HS, Decker RH. Post-operative radiation therapy for non-small cell lung cancer: A comparison of radiation therapy techniques. Lung Cancer 2021, 161: 171-179. PMID: 34607209, DOI: 10.1016/j.lungcan.2021.09.010.Peer-Reviewed Original ResearchConceptsPost-operative radiation therapyNon-small cell lung cancerCell lung cancerRadiation therapyPropensity-score matchingLA-NSCLCCardiac toxicityLung cancerAdvanced non-small cell lung cancerClinical risk factorsProportion of patientsMultivariable logistic regressionPrior treatment historyPredictors of receiptUse of IMRTConformal radiation therapyLong-term toxicityChi-squared testRadiation therapy techniquesRadiotherapy treatment techniquesUpfront surgeryElderly patientsTreatment toxicityMean ageMedicare databaseRates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ
Talcott WJ, Miccio JA, Park HS, White AA, Kozono DE, Singer L, Sands JM, Sholl LM, Detterbeck FC, Mak RH, Decker RH, Kann BH. Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ. Lung Cancer 2021, 157: 17-20. PMID: 34052704, DOI: 10.1016/j.lungcan.2021.05.028.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerBiopsy suggestiveInvasive diseaseSitu diseaseSquamous histologySurvival outcomesTumor sizeObserved cohortNational Cancer DatabaseExcellent survival outcomesHalf of patientsCell lung cancerMultivariable logistic regressionResection of lesionsAdenocarcinoma histologyDefinitive therapyNSCLC patientsOverall survivalLocal therapyRisk stratificationLung cancerCancer DatabaseResectionSurgical pathologyLesion sizeAdoption of consolidative durvalumab among patients with locally advanced non-small cell lung cancer.
Jairam V, Pasha S, Soulos P, Goldberg S, Yu J, Decker R, Gross C, Park H. Adoption of consolidative durvalumab among patients with locally advanced non-small cell lung cancer. Journal Of Clinical Oncology 2021, 39: e20550-e20550. DOI: 10.1200/jco.2021.39.15_suppl.e20550.Peer-Reviewed Original ResearchNon-small cell lung cancerCell lung cancerTumor characteristicsLung cancerFDA approvalConsolidative durvalumabPatient characteristicsUnresectable stage III non-small cell lung cancerStage III non-small cell lung cancerAdvanced non-small cell lung cancerFirst-line platinum-doublet chemotherapyStudy periodFlatiron Health databasePlatinum-doublet chemotherapyGuideline-concordant carePD-L1 statusMultivariable logistic regressionCochran-Armitage testDe-identified databaseChi-square testDefinitive chemoradiationDoublet chemotherapyEligible patientsPACIFIC trialSurgery detailsPrevalence of Missing Data in the National Cancer Database and Association With Overall Survival
Yang DX, Khera R, Miccio JA, Jairam V, Chang E, Yu JB, Park HS, Krumholz HM, Aneja S. Prevalence of Missing Data in the National Cancer Database and Association With Overall Survival. JAMA Network Open 2021, 4: e211793. PMID: 33755165, PMCID: PMC7988369, DOI: 10.1001/jamanetworkopen.2021.1793.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseNon-small cell lung cancerOverall survivalCell lung cancerCancer DatabaseMedical recordsLung cancerProstate cancerBreast cancerPatient recordsComplete dataRetrospective cohort studyCohort studyCancer RegistryCommon cancerVariables of interestHigh prevalenceMAIN OUTCOMEPatientsClinical advancementReal-world data sourcesCancerPrevalenceSurvivalHeterogeneous differences
2020
Post-Operative Radiation Therapy for Non-Small Cell Lung Cancer: A Comparison of Radiation Therapy Techniques
Jairam V, Pasha S, Soulos P, Gross C, Yu J, Park H, Decker R. Post-Operative Radiation Therapy for Non-Small Cell Lung Cancer: A Comparison of Radiation Therapy Techniques. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e130. DOI: 10.1016/j.ijrobp.2020.07.1276.Peer-Reviewed Original ResearchNon-small cell lung cancerPost-operative radiation therapyComparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non–small cell lung cancer: A network meta‐analysis of randomized trials
Pathak R, De Lima Lopes G, Yu H, Aryal MR, Ji W, Frumento KS, Wallis CJD, Klaassen Z, Park HS, Goldberg SB. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non–small cell lung cancer: A network meta‐analysis of randomized trials. Cancer 2020, 127: 709-719. PMID: 33119177, DOI: 10.1002/cncr.33269.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerSingle-agent ICICell lung cancerPD-L1Lung cancerAdditional overall survival benefitsEfficacy of chemoimmunotherapyFirst-line ICIHigh PD-L1Overall survival benefitCochrane Central RegisterFirst-line treatmentPD-L1 statusPhase 3 trialLow PD-L1Absence of headSignificant differencesRandom-effects modelBayesian random-effects modelImproved PFSOS benefitEfficacy outcomesEligible trialsCentral RegisterComparative efficacy of chemoimmunotherapy versus immunotherapy alone in the front-line treatment of advanced non-small cell lung cancer: A systematic review and network meta-analysis.
Pathak R, Lopes G, Yu H, Ji W, Aryal M, Frumento K, Wallis C, Klaassen Z, Park H, Goldberg S. Comparative efficacy of chemoimmunotherapy versus immunotherapy alone in the front-line treatment of advanced non-small cell lung cancer: A systematic review and network meta-analysis. Journal Of Clinical Oncology 2020, 38: 9552-9552. DOI: 10.1200/jco.2020.38.15_suppl.9552.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsIpi/nivoPD-1 axis inhibitorsPD-L1 1Phase 3 RCTsPD-L1 statusPD-L1Advanced non-small cell lung cancerSingle-agent immune checkpoint inhibitorsSystematic reviewCombination immune checkpoint inhibitorsNon-small cell lung cancerDual checkpoint blockadeCTLA-4 inhibitorsFront-line treatmentCell lung cancerSignificant differencesAdvanced NSCLCICI monotherapyOS benefitCheckpoint inhibitorsProspective trialCheckpoint blockadeCombination chemotherapyNSCLC patientsLocal Ablative Therapies for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
Jairam V, Park HS, Decker RH. Local Ablative Therapies for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer. The Cancer Journal 2020, 26: 129-136. PMID: 32205537, DOI: 10.1097/ppo.0000000000000433.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerLocal ablative therapyOligoprogressive non-small cell lung cancerCell lung cancerAblative therapyMetastatic diseaseLung cancerMetastatic non-small cell lung cancerTime of diagnosisLong-term survivalLimited metastasesOligometastatic diseaseMetastatic patientsSystemic therapyRadiofrequency ablationDisease progressionPatient outcomesStereotactic radiotherapyTherapyPatientsDiseaseAccumulation of evidenceCancerProgressionComplex diseases
2018
Association Between Radiation Dose and Outcomes With Postoperative Radiotherapy for N0-N1 Non–Small Cell Lung Cancer
Wang EH, Corso CD, Park HS, Chen AB, Wilson LD, Kim AW, Decker RH, Yu JB. Association Between Radiation Dose and Outcomes With Postoperative Radiotherapy for N0-N1 Non–Small Cell Lung Cancer. American Journal Of Clinical Oncology 2018, 41: 152-158. PMID: 26523443, DOI: 10.1097/coc.0000000000000245.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAgedCarcinoma, Non-Small-Cell LungCohort StudiesDatabases, FactualDisease-Free SurvivalDose-Response Relationship, RadiationFemaleHumansLung NeoplasmsMaleMargins of ExcisionMiddle AgedMultivariate AnalysisNeoplasm InvasivenessNeoplasm StagingPneumonectomyPrognosisProportional Hazards ModelsRadiotherapy DosageRadiotherapy, AdjuvantRadiotherapy, Intensity-ModulatedRetrospective StudiesSurvival AnalysisTreatment OutcomeConceptsNon-small cell lung cancerPostoperative radiotherapyCell lung cancerIntensity-modulated radiation therapyPORT doseOverall survivalLung cancerRadiation therapyUse of PORTNational Cancer Data BaseStage IIProportion of patientsGroup of patientsProportional hazards regressionEvidence of benefitSurgical resectionWorse survivalMultivariable analysisHazards regressionRetrospective studyConformal radiationPatientsRadiotherapy techniquesRadiation modalitiesModern treatment
2017
Radiosurgery for Brain Metastases: Changing Practice Patterns and Disparities in the United States.
Kann BH, Park HS, Johnson SB, Chiang VL, Yu JB. Radiosurgery for Brain Metastases: Changing Practice Patterns and Disparities in the United States. Journal Of The National Comprehensive Cancer Network 2017, 15: 1494-1502. PMID: 29223987, DOI: 10.6004/jnccn.2017.7003.Peer-Reviewed Original ResearchConceptsNational Cancer Data BaseStereotactic radiosurgeryBrain metastasesPractice patternsBrain radiotherapyMetastatic diseaseMetastatic non-small cell lung cancerNon-small cell lung cancerNon-SR patientsUpfront brain radiotherapyNational practice patternsProportion of patientsKaplan-Meier methodCell lung cancerProportion of facilitiesQuality of lifeChi-square testActuarial survivalIntracranial controlNeurocognitive toxicityNonprivate insuranceSRS useNCDB analysisDiagnosis yearMultivariable analysisIncreasing Utilization of Stereotactic Radiation Therapy as a Component of Initial Therapy in Metastatic Non–small Cell Lung Cancer
Hayman T, Bledsoe T, Corso C, Lester-Coll N, Park H, Decker R. Increasing Utilization of Stereotactic Radiation Therapy as a Component of Initial Therapy in Metastatic Non–small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e459. DOI: 10.1016/j.ijrobp.2017.06.1702.Peer-Reviewed Original Research
2016
Elderly patients undergoing SBRT for inoperable early-stage NSCLC achieve similar outcomes to younger patients
Mancini BR, Park HS, Harder EM, Rutter CE, Corso CD, Decker RH, Husain ZA. Elderly patients undergoing SBRT for inoperable early-stage NSCLC achieve similar outcomes to younger patients. Lung Cancer 2016, 97: 22-27. PMID: 27237023, DOI: 10.1016/j.lungcan.2016.04.011.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerEarly-stage non-small cell lung cancerStereotactic body radiation therapyNon-elderly patientsElderly patientsDistant controlOverall survivalYounger patientsInoperable early-stage non-small cell lung cancerUse of SBRTStage non-small cell lung cancerLocal controlMultivariable Cox proportional hazards analysisCox proportional hazards analysisGrade 5 toxicityNon-elderly cohortProportional hazards analysisCell lung cancerRisk of complicationsRate of efficacyBody radiation therapyLogistic regression analysisLate gradeAcute gradeSurgical resection
2015
Survival Comparison of 3 Versus 4-5 Fractions for Stereotactic Body Radiation Therapy in Stage I Non-Small Cell Lung Cancer
Park H, Corso C, Rutter C, Kim A, Yu J, Husain Z, Decker R. Survival Comparison of 3 Versus 4-5 Fractions for Stereotactic Body Radiation Therapy in Stage I Non-Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: s100. DOI: 10.1016/j.ijrobp.2015.07.240.Peer-Reviewed Original ResearchAssociation Between Radiation Dose and Outcomes With Postoperative Radiation Therapy for N0-N1 Non-Small Cell Lung Cancer
Wang E, Corso C, Park H, Chen A, Kim A, Wilson L, Decker R, Yu J. Association Between Radiation Dose and Outcomes With Postoperative Radiation Therapy for N0-N1 Non-Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e387-e388. DOI: 10.1016/j.ijrobp.2015.07.1536.Peer-Reviewed Original ResearchHigher Facility Case Volume of Stereotactic Body Radiation Therapy Is Associated With Improved Overall Survival in Clinical Stage I Non-Small Cell Lung Cancer
Park H, Wang E, Corso C, Rutter C, Wilson L, Kim A, Gross C, Yu J, Decker R. Higher Facility Case Volume of Stereotactic Body Radiation Therapy Is Associated With Improved Overall Survival in Clinical Stage I Non-Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: s186-s187. DOI: 10.1016/j.ijrobp.2015.07.447.Peer-Reviewed Original ResearchPostoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small Cell Lung Cancer
Wang E, Corso C, Rutter C, Park H, Chen A, Kim A, Wilson L, Decker R, Yu J. Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e388-e389. DOI: 10.1016/j.ijrobp.2015.07.1538.Peer-Reviewed Original Research